General Information of the Drug (ID: M6APDG03870)
Name
Ferroportin mab
Status
Phase 1
TTD Drug ID
D07SQT
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Solute carrier family 40 member 1 (SLC40A1)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
Response Summary Solute carrier family 40 member 1 (SLC40A1) is a therapeutic target for Ferroportin mab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ferroportin mab through regulating the expression of Solute carrier family 40 member 1 (SLC40A1). [1], [2]
References
Ref 1 N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat Commun. 2022 May 13;13(1):2672. doi: 10.1038/s41467-022-30217-7.
Ref 2 Hepcidin agonists as therapeutic tools. Blood. 2018 Apr 19;131(16):1790-1794. doi: 10.1182/blood-2017-11-737411. Epub 2018 Mar 9.